Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended December 31, 2022. OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUMOS PHARMA, INC. (Exact name of Registrant as specified in its Charter) Delaware 42-1491350 (State or other juris ...

Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Lisa Miller - Senior Director, IR Richard Hawkins - CEO & Chairman Lori Lawley - CFO & Principal Accounting Officer John McKew - Chief Scientific Officer & President David Karpf - Chief Medical Officer Conference Call Participants Peter Rosenthal - Cantor Catherine Novack - Jones Trading Eun Yang - Jefferies Ed White - H.C. Wainwright & Co. Operator Good afternoon, and welcome to Lumos Pharma's 20 ...

P H A R M A 1 Interim Analysis OraGrowtH210 & OraGrowtH212 November 14, 2022 Forward Looking Statements 2 This presentation contains proprietary and confidential information of Lumos Pharma, Inc. ("Lumos," "we," "us" and "our"), and such content should be considered "Confidential Information" and covered by your confidentiality obligations to Lumos. This presentation is made solely for informational purposes, and no representation or warranty, express or implied, is made by Lumos or any of its representativ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended September 30, 2022. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUMOS PHARMA, INC. (Exact name of Registrant as specified in Its Charter) Delaware 42-1491350 (State or other ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended June 30, 2022. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUMOS PHARMA, INC. (Exact name of Registrant as specified in Its Charter) Delaware 42-1491350 (State or other juri ...

Lumos Pharma, Inc. (NASDAQ:LUMO) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Lisa Miller - Senior Director of Investor Relations Richard Hawkins - Chairman and Chief Executive Officer Lori Lawley - Chief Financial Officer John McKew - President and Chief Scientific Officer David Karpf - Chief Medical Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald, L.P Emma Nesson - Piper Sandler & Co. Edward White - H.C. Wainwright & Co, LLC Catherine Novack - Jon ...

Second Quarter 2022 Financial Results & Clinical Update 1 August 9, 2022 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this presentation are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, a law that gives us the opportunity to share our outlook for the future without fear of litigation if it turns out our predictio ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended March 31, 2022. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. (Address, including zip code, and telephone number, including area code, of principal executive offices) For the transition period from to . Commission File Number 001-35342 LUMOS PH ...

P H A R M 1 First Quarter 2022 Financial Results & Clinical Update May 10, 2022 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this presentation are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, a law that gives us the opportunity to share our outlook for the future without fear of litigation if it turns out our pr ...

Lumos Pharma, Inc. (NASDAQ:LUMO) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Lisa Miller - Senior Director, IR Richard Hawkins - CEO & Chairman John McKew - Chief Scientific Officer & President David Karpf - Chief Medical Officer Lori Lawley - CFO & Principal Accounting Officer Conference Call Participants Avraham Novick - Cantor Fitzgerald & Co. Yasmeen Rahimi - Piper Sandler & Co. Catherine Novack - JonesTrading Institutional Services Edward White - H.C. Wainwright & Co. ...